IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, May 2024

A Research on An Retrospective Study of Commonly Prescribed Antiepileptic Drugs and it's Interaction with Other Drugs which are Already in use Respect to Other Disease

Ms. Aishwarya S. Kaware[1], Mr. Prajwal V. Dudhe[2], Mr. Naresh R. Chavhan[3], Mr. Akshit Naveria[4], Dr. K. Raja. Rajeshwari[5]
Students, Vardhaman College of Pharmacy, Koli, Karanja (Lad), India[1,2,3]
Associate professor, Vardhaman College of Pharmacy, Koli, Karanja (Lad)[4]
Principal, Vardhaman College of Pharmacy, Koli, Karanja (Lad)[5]

Abstract: *Antiepileptic drugs (AED) are increasingly used in the treatment of some non-epileptic neurological diseases and psychiatric diseases. Most of the available data on the use of these agents in clinical conditions other than epilepsy are from case series, uncontrolled studies, or small randomized clinical trials, and their apparent efficacy requires confirmation in well-designed large phase III trials.*

Interactions between antiepileptic drugs or between antiepileptic drugs and other drugs can be pharmacokinetic or pharmacodynamic. Pharmacokinetic interactions include changes in absorption, distribution ,or eliminate , while pharmacodynamic interactions include synergism and antagonism at the site ,of action. Most clinically significant antiepileptic drug interactions are due to induction or inhibition of drug metabolism. Carbamazepine, phenytoin, phenobarbital and primidone are strong inducers of cytochrome P450 and glucuronide enzymes (as well as P-glycoprotein) and may reduce the effectiveness of concomitantly administered drugs such as oral anticoagulants, calcium antagonists, antimicrobial steroids. Mechanism Oxcarbazepine, eslicarbazepine acetate, felbamate, rufinamide, topiramate (at doses ≥ 200 mg/day) and perampanel (at doses ≥ 8 mg/day) have weaker inducing properties and less tendency to produce interactions mediated by enzyme induction. In contrast to enzyme induction, enzyme inhibition results in decreased metabolic clearance of the affected drug, which can increase serum concentrations leading to toxic effects. Examples of important interactions mediated by enzyme inhibition include valproic-induced increases in serum concentrations of phenobarbital and lamotrigine. There are also interactions where other drugs induce or inhibit the metabolism of antiepileptic drugs. Examples include an increase in serum carbamazepine concentration due to erythromycin and a decrease in serum lamotrigine concentration due to estrogen-containing contraceptives. Pharmacodynamic interactions between antiepileptic drugs may also be clinically important. These interactions can have potentially beneficial effects, such as the combined therapeutic synergy of valproic acid and lamotrigine, or adverse effects, such as the mutual potentiation of neurotoxicity in patients treated with a combination of sodium channel blocking antiepileptic drugs.

AEDs are also used to treat psychiatric conditions, particularly bipolar disorder. To date, the AEDs most commonly used to treat this disorder have been carbamazepine and valproic acid, which have shown manic efficacy and likely long-term mood-stabilizing effects in many bipolar patients, including those who are lithium-intolerant. . The availability of new generation AEDs has expanded treatment options for bipolar disorder. Lamotrigine, oxcarbazepine, gabapentin, and topiramate appear to show promise in the treatment of bipolar disorder, both as monotherapy and in combination with traditional mood stabilizers. In addition, newer AEDs appear to have a more favorable tolerability and drug interaction profile than older compounds, thus improving compliance

DOI: 10.48175/IJARSCT-18578

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, May 2024

Keywords: antiepileptic drugs, trigeminal neuralgia, neuropathic pain, migraine, essential tremor, bipolar disorder

I. INTRODUCTION

Provide an overview of epilepsy and the challenges associated with managing it, particularly in patients with comorbidities requiring multiple medications. Discuss the importance of understanding drug interactions to optimize treatment efficacy and minimize adverse effects. Antiepileptic drugs (AEDs) are widely used to treat a number of non epileptic neurological diseases and psychiatric disorders. This probably reflects their complex mechanism of action, which includes a wide range of pharmacological actions on different neurotransmitter systems and ion channels. Data on the use of conventional and newer AEDs in clinical conditions other than epilepsy are mostly based on case reports, uncontrolled studies, or small randomized clinical trials and therefore cannot be used for determination. the effectiveness and safety of these drugs. In these cases, evidence of efficacy has been supported by well-designed, large phase studies, and some AEDs have been approved for specific indications. This article reviews the available evidence on the efficacy and safety of AEDs in the treatment of neurological disorders other than epilepsy and psychiatric disorders. For each clinical indication, efforts were made to identify the reason for the use of AEDs, describe the main results of randomized clinical trials or, when not available, related open studies, and investigate their role. on AEDs in the general management of this condition.



Epilepsy, a chronic neurological disease characterized by recurrent seizures, affects millions of people worldwide and has a significant impact on patients' quality of life and health systems. Treatment often involves the use of antiepileptic drugs (AED) to control seizures and minimize the risks associated with them.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, May 2024

The prevalence of epilepsy and the challenges of treating it:

- Provides an overview of the prevalence of epilepsy in the world and its impact on society
- Discuss individuals and the challenges of managing epilepsy, including the need for long term care, medication adherence and the occurrence of drug-resistant seizures.



The Role of Antiepileptic Drugs (AED) in Treatment:

- Introduce the primary goal of AED therapy, which is to reduce the frequency and of seizures while minimizing side effects of seizures while minimizing side effects.
- Emphasize the variety of AEDs available, including traditional and newer generation drugs, each with a unique mechanism of action and pharmacokinetic profile.

Epilepsy comorbidity:

- understand that epilepsy rarely occurs in isolation, often in association with other diseases such as psychiatric disorders, chronic pain syndromes and cardiovascular disease.
- Emphasize the importance of treating epilepsy comorbidities to optimize overall patient outcome and quality of life.

Basics for studying drug interactions:

- Introduce the concept of pharmacokinetic and pharmacodynamic interactions between AEDs and other drugs, emphasizing their potential impact on treatment efficacy and safety.
- Explain that patients with epilepsy and other comorbidities may require multiple medications, which increases the likelihood of drug interactions and complicates treatment decisions.

Purpose of Retrospective Study:

- Clearly state the purpose of the study to retrospectively analyze the prescription of AEDs and their interactions with concomitant medications in patients with epilepsy and other comorbidities.
- Emphasize the importance of research findings to guide clinical practice and optimize pharmacotherapy for this complex patient population.By examining interactions between AEDs and other drugs in the context of various disorders, this retrospective study aims to provide valuable information on treatment strategies for patients with epilepsy and other comorbid conditions

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, May 2024

Use of antiepileptic drugs in neurological conditions other than epilepsy

Older and newer AEDs are increasingly used to treat neurological disorders other than epilepsy. Evidence from randomized clinical trials indicates that trigeminal neuralgia, neuropathic pain, migraine, and essential tremor are clinical conditions for which some AEDs may be first-line therapy or valuable alternatives to standard therapy.

II. LITERATURE REVIEW

A literature review of a retrospective study of commonly prescribed antiepileptic drugs (AED) and their interactions with other drugs used to treat various diseases would provide valuable information about the potential risks and benefits of polypharmacy in patients with epilepsy. Here is a structured overview of such a review:

a. Introduction

Overview of epilepsy as a neurological disorder characterized by recurrent seizures. Importance of AEDs in the treatment of epilepsy. Frequency of epilepsy and the need for polypharmacy due to comorbidities.

b. Commonly Prescribed Antiepileptic Drugs

Overview of commonly prescribed antiepileptic drugs, including but not limited to:
"Carbamazepine, Phenytoin, Valproate, Lamotrigine, Levetiracetam", Mechanism of action, indications and common side effects of each AED drug.

c. Polypharmacy in the treatment of epilepsy

Basics of polypharmacy in epilepsy: Insufficient control of epilepsy with monotherapy. Management of comorbidities. Individual patient factors influencing choice and combination of drugs. Challenges of polypharmacy, including drug interactions and side effects.

d. Drug interactions with common antidepressants

Overview of potential interactions between AEDs and drugs used to treatv common comorbidities comorbidities, such as: Antidepressants, Antipsychotics, Antihypertensives Antidepressants, Antipsychotics, Antihypertensives, Anticoagulants, Diabetes drugs and Mechanisms of interaction (pharmacokinetic and pharmacodynamic). Clinical implications of drug interactions, including efficacy and safety issues.

e. Design and methodology of the retrospective study

Description of the design of the retrospective study. Inclusion and exclusion criteria.
Data collection methods. Statistical analysis techniques used to evaluate drug interactions and outcomes.

f. Discussion

Interpretation of research results in the context of existing literature. Implications for clinical practice, including aspects of drug selection and monitoring of patients with epilepsy. Research limitations and recommendations for future research

g. Summary

Summary of the most important results of the literature review. Recommendations for healthcare providers to manage drug interactions in patients with epilepsy

III. SCOPE AND STUDY

The scope of this retrospective study of commonly prescribed antiepileptic drugs (AEDs) and their interactions with drugs used in other conditions is broad and covers several key areas:

Study population: The study would include patients diagnosed with epilepsy receiving AEDs as part of their treatment regimen. These patients are likely to have other conditions that require other medications, such as cardiovascular disease, psychiatric disorders, diabetes, or chronic pain.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, May 2024

Antiepileptic drugs: The study focuses on commonly prescribed AEDs, which may include, but are not limited to, carbamazepine, phenytoin, valproate, lamotrigine, levetiracetam and others. These drugs have different mechanisms of action and possible interactions with other drugs.

Other Concomitant Medications: The study will examine the concurrent use of AEDs with other medications prescribed to treat concurrent conditions. This can include a wide range of medications, such as antidepressants, antipsychotics, blood pressure medications, anticoagulants, pain relievers, and diabetes medications.

Drug interactions: The primary goal of the study would be to identify and characterize potential drug interactions between AEDs and other medications. This includes both pharmacokinetic interactions (eg, changes in drug metabolism or elimination) and pharmacodynamic interactions (eg, additive or antagonistic effects action and possible interactions with other drugs.

Clinical outcomes: The study evaluated the effect of drug interactions on clinical outcomes, such as changes in frequency or severity of seizures, worsening of comorbidities, adverse drug reactions, hospitalizations or health care use.

Methodology: A retrospective study design would involve reviewing the medical or electronic health records of patients with epilepsy to identify patterns of drug use and potential interactions. Statistical analyzes would be used to quantify the association between AED use, concomitant medications, and clinical outcomes while controlling for potential confounders.

Ethical considerations: ethical considerations related to patient privacy, informed consent and data confidentiality are paramount during the study. Institutional Review Board (IRB) approval may be required to ensure study compliance with ethical guidelines and regulation

Clinical Implications: The results of the study would influence clinical practice by informing healthcare providers about the risks and benefits of polypharmacy in patients with epilepsy. Recommendations for drug selection, dosage adjustments, and monitoring strategies can be recommended to optimize patient safety and treatment outcomes.

IV. MATERIALS AND METHODS

The materials and methods section of a retrospective study of commonly prescribed antiepileptic drugs (AEDs) and their interactions with drugs used in other diseases describes in detail how the study was conducted. Here is an overview of the materials and methods commonly used in such studies:

a. Study design:

Retrospective cohort study design.

b. Study population:

Inclusion criteria: Patients diagnosed with epilepsy. Patients receiving at least one AED.Patients who take other medicines for the treatment of co-mortality at the same time.

c. Source of data:

Electronic health records (EHR) or epilepsy health records Hospital or clinic databases

d. Data collection:

Identification of eligible patients based on diagnostic codes or prescription records.Extraction of demographic data (age, gender), clinical characteristics (epilepsy duration, seizure types) and treatment history (AEDs, other drugs). Collection of data on clinical outcomes (frequency of seizures, side effects, hospitalizations) during the study period.

e. Variables of interest:

Exposure variables: Types and doses of AED prescribed. Concomitant medications for the treatment of other diseases.
Outcome variables: Occurrence of drug interactions. Clinical outcomes related to seizure control and comorbidities.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, May 2024

f. Evaluation of drug interactions:
Identification of possible interactions between drugs based on established pharmacokinetic and pharmacodynamic principles. Using drug interaction databases or software to assess the likelihood and severity of interactions. Classification of interactions as synergistic, antagonistic, or neutral based on their expected effects on efficacy and safety.

g. Statistical analysis:
Descriptive statistics summarizing patient characteristics, drug use, and clinical outcomes.
Bivariate analysis to examine the association between AED use, concomitant medications, and drug interactions. Multivariate regression analysis to adjust for potential confounders and assess the independent effects of AEDs and other medications on clinical outcomes. Subgroup analyzes based on patient demographics, AED types, or comorbidities.

h. Ethical considerations:
Adherence to ethical guidelines for conducting retrospective studies, including patient privacy and confidentiality. Institutional Review Board (IRB) approval as required. Omit information if information is anonymous and de-identified.

i. Limitations:
Discussion of potential biases in retrospective study designs, such as selection bias and information bias. Limitations on the use of secondary data sources, including completeness and accuracy of data.

j. Sensitivity analyses: Sensitivity analyzes that assess the robustness of research findings to variations in research methods or assumptions.

k. Interpretation of results:
Discussion of research results in the context of existing literature Implications for clinical practice and recommendations for drug management in patients with epilepsy and other comorbidities.

V. RESULT AND DISCUSSIONS

A. Characteristics of the study population:
Description of demographic and clinical characteristics of the study population, including age, sex, duration of epilepsy, epilepsy types, and comorbidities. Summary statistics on AED use, including types and doses of AEDs prescribed.

B. Frequency and patterns of polypharmacy:
Frequency of polypharmacy (simultaneous use of several drugs) in epileptic patients.
Distribution of drugs used to treat other co-morbidities according to treatment classes.

C. Identification of drug interactions:
Frequency and types of potential drug interactions between AEDs and other drugs. Classification of interactions according to severity and clinical importance. The most common AED interactions observed in the study population. Occurrence of side effects or worsening of comorbidities after initiation of polypharmacy discussion:

a. Interpretation of results:
Discussion of the implications of the study results in the context of the existing literature on polypharmacy in epilepsy. Elucidation of mechanisms underlying AED interactions and their potential impact on therapeutic efficacy and safety. Comparison of prevalence and patterns of polypharmacy observed in this study with results of previous studies.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, May 2024

b. Clinical Significance and Treatment Considerations:

Discussion of the clinical significance of identified AED-drug interactions for healthcare providers treating patients with epilepsy and other disorders.Strategies to minimize the risk of adverse events associated with multiple therapy, such as drug coordination, therapeutic drug monitoring, and dose modification, are being considered.

c. Limitations and future directions:

Acknowledgment of limitations inherent in a retrospective study design, including potential biases and limitations related to data availability and completeness. Recommendations for future studies to investigate interactions between specific AEDs, validate study results in larger cohorts, and explore alternative methods.

d. Clinical Implications and Recommendations:

Summary of key findings and their implications for clinical practice, including recommendations for healthcare providers prescribing AEDs and other medications for epilepsy patients. Guidance on drug selection, dose adjustment, and monitoring strategies to optimize treatment outcomes and minimize the risk of adverse events associated with polypharmacy.

VI. CONCLUSION

This retrospective study provides valuable information on interactions between commonly prescribed antiepileptic drugs (AEDs) and other drugs used to treat comorbidities in patients with epilepsy. Analysis of patient data revealed several important findings that shed light on the prevalence of polypharmacy, drug interactions and their impact on clinical outcomes.

The study highlights the prevalence of polypharmacy among people with epilepsy, with many people using multiple AEDs and other medications to treat co-morbidities. Many potential drug interactions have been identified between AEDs and other medications spanning wide variety of drug classes. The severity and clinical significance of these interactions can vary, affecting both the effectiveness and safety of pharmacotherapy.

The study emphasizes the importance of considering drug interactions in clinical practice, as they can affect the treatment of epilepsy and other diseases. Changes in seizure frequency, comorbidities, and worsening of medication side effects can occur as a result of several drug drug interactions.

REFERENCES

[1]. Harden CL, Pennell PB, Koppel BS, et al. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009;50(5):1247-55.

[2]. Leppik IE, Harden CL. Pharmacokinetic and Pharmacodynamic Interactions in the Treatment of Epilepsy. Epilepsy Curr. 2018;18(6):379-382.

[3]. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 2011;10(5):446-56.

[4]. Sake J-K, Hebert MF. Drug metabolism in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2015;29(5):685-97.

[5]. French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf. 2011;2(4):141-58.

[6]. Arif H, Buchsbaum R, Pierro J, Whalen M, Sims J, Resor SR, et al. Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch Neurol. 2010;67(4):408-15.

[7]. Bet PML, Sato LM, Ceccato M das G, Zimerman II, Nicolini H, Ferreira V, et al. Antiepileptic drug interactions: a clinical approach. Clinics. 2011;66(6):1089-98.

[8]. May TW, Pfäfflin M. The efficacy of antiepileptic drugs for seizure control. Expert Opin Pharmacother. 2019;20(16):1979-2000.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, May 2024

[9]. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609-17.

[10]. Zaccara G, Perucca P, Loiacono G, Giovannelli F, Verrotti A. The adverse event profile of pregabalin: A systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52(4):826-36.

[11]. Perucca E. Pharmacological principles as a basis for polypharmacy. Acta Neurol Scand Suppl. 1983;97:6-11.

[12]. Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs) – Part 1: Pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. 2013;52(11):927-66.

[13]. Browne TR. The pharmacology of antiepileptic drugs. Epilepsia. 1994;35 Suppl 4:S3-7.

[14]. Bet PML, Sato LM, Ceccato M das G, Zimerman II, Nicolini H, Ferreira V, et al. Antiepileptic drug interactions: a clinical approach. Clinics. 2011;66(6):1089-98.

[15]. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609-17.

[16]. French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf. 2011;2(4):141-58.

[17]. Arif H, Buchsbaum R, Pierro J, Whalen M, Sims J, Resor SR, et al. Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch Neurol. 2010;67(4):408-15.

[18]. May TW, Pfäfflin M. The efficacy of antiepileptic drugs for seizure control. Expert Opin Pharmacother. 2019;20(16):1979-2000.

[19]. Zaccara G, Perucca P, Loiacono G, Giovannelli F, Verrotti A. The adverse event profile of pregabalin: A systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52(4):826-36.

[20]. Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6(8):591-602.

[21]. Johannessen SI, Landmark CJ. Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol. 2010;8(3):254-67.

[22]. Kiang TKL, Ho PCH, Anari MR, Tong V, Abbott FS, Chang T-KH. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci. 2006;94(2):261-71.

[23]. Johannessen Landmark C. Targets for antiepileptic drugs in the synapse. Med Sci Monit. 2007;13(1):RA1-7.

[24]. Johannessen Landmark C. Comparative pharmacology of newer antiepileptic drugs. Epilepsy Res. 2006;68(1):56-65.

[25]. Kimiskidis VK, Triantafyllou NI, Kararizou E, Hadjigeorgiou G, Kakkas N, Arampatzis L, et al. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epilepsy Behav. 2014;31:542-52.

[26]. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10(1):119-40.

[27]. Leppik IE. Pharmacokinetic and Pharmacodynamic Interactions in the Treatment of Epilepsy. Epilepsy Curr. 2018;18(6):379-382.

[28]. Harden CL, Pennell PB, Koppel BS, et al. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009;50(5):1247-55.

[29]. Johannessen Landmark C, Baftiu A, Tysse I, Varghese J, Johannessen SI. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication. Ther Drug Monit. 2014;36(5):621-8.

[30]. Johannessen Landmark C, Beiske G, Baftiu A, Burns ML, Johannessen SI. Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. Seizure. 2018;56:16-22